Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

103.36 +0.79 (+0.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Analyst Ratings for Axsome Therapeutics
Via Benzinga
Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day
From Axsome Therapeutics, Inc.
Via GlobeNewswire
2 Top Biotech Stocks Defying the Bear Market
The best may be yet to come for these companies. 
Via The Motley Fool
2 No-Brainer Biotech Stocks to Buy Right Now
You can get in early on these potential winners. 
Via The Motley Fool
Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Analyst Ratings for Axsome Therapeutics
Via Benzinga
Expert Ratings for Axsome Therapeutics
Via Benzinga
Why Shares of Axsome Therapeutics Fell Wednesday
The biopharmaceutical company announced a $225 million stock sale. 
Via The Motley Fool
Axsome Therapeutics to Present at Three Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
The Top Healthcare Stocks to Buy With $100
Both stocks have outperformed the broader market in the last 12 months. 
Via The Motley Fool
These 3 Stocks Have Underperformed the Market This Year. Is Now the Time to Buy?
Today's market loser could be tomorrow's market winner. 
Via The Motley Fool
Got $200? 3 Growth Stocks to Buy That Could Double Your Money
There's no guarantee that any stock will deliver 2 times returns. But the chances for these stocks look pretty good. 
Via The Motley Fool
Axsome Therapeutics Stock Earns Relative Strength Rating Upgrade
A Relative Strength Rating upgrade for Axsome Therapeutics shows improving technical performance. 
Via Investor's Business Daily
3 Explosive Stocks to Buy Right Now
These stocks are poised to pop in the not-too-distant future. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023
Via Benzinga
DraftKings To Rally Over 38%? Here Are 10 Other Analyst Forecasts For Tuesday
Piper Sandler raised the price target for Chegg, Inc. (NYSE: CHGG) from $11 to $13. Piper Sandler analyst Arvind Ramnani maintained a Neutral rating. Chegg shares rose 19.9% to $12.03 in pre-market... 
Via Benzinga
FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says
Axsome Therapeutics Inc (NASDAQ: AXSM) reported Q2 sales of $46.7 million, beating the consensus of $40.19 million.  
Via Benzinga
Axsome Therapeutics (AXSM) Q2 2023 Earnings Call Transcript
AXSM earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
3 Fantastic Growth Stocks to Buy in August
These stocks could be poised to soar. 
Via The Motley Fool
Got $5,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond
There's lots of upside potential for these drugmakers. 
Via The Motley Fool
The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023
These are the three bargain biotech stocks showcasing massive upside potential for investors looking to find a position in the sector. 
Via InvestorPlace
Baidu To Rally Around 32%? Here Are 10 Other Analyst Forecasts For Monday
Keybanc boosted the price target for Camping World Holdings, Inc. (NYSE: CWH) from $28 to $36. Keybanc analyst Noah Zatzkin maintained an Overweight rating. Camping World shares rose 1.4% to $32.04 in... 
Via Benzinga
Got $500? 3 Growth Stocks to Buy That Could Double Your Money
There's no guarantee these stocks will deliver 2x returns over the next few years, but their prospects look good. 
Via The Motley Fool
Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7
Axsome to host conference call and webcast on Monday, Aug. 7, 2023, at 8:00 a.m. Eastern Time 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults
From Axsome Therapeutics, Inc.
Via GlobeNewswire
5 Top Stocks for July
This basket of stocks has it all, including growth, dividend income, and value. 
Via The Motley Fool
Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Why Eton Pharmaceuticals Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) surged 46.2% to $8.80. Minerva Neurosciences announced $20 million in private placement priced at a premium to market. 
Via Benzinga
Why Is Xponential Fitness (XPOF) Stock Up 19% Today?
Xponential Fitness (XPOF) stock is climbing higher on Wednesday as the company strikes back against a short report from Fuzzy Panda Research. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.